Incorporating target heterogeneity in drug design

Adrian Velazquez-Campoy, Ernesto I Freire

Research output: Contribution to journalArticle

Abstract

Traditionally, structure-based drug design has been predicated on the idea of the lock-and-key hypothesis, i.e., the ideal drug should have a structure that complements the target site structurally and energetically. The implementation of this idea has lead to the development of drug molecules that are conformationally constrained and pre-shaped to the geometry of the selected target. The main drawback of this strategy is that conformationally constrained molecules cannot accommodate to variability in the target and, therefore, lose significant binding affinity even in the presence of small changes in the target site. There are three common situations that lead to binding site heterogeneity: (1) genetic diversity; (2) drug resistant mutations; and (3) binding site dynamics. The development of drugs that effectively deal with target heterogeneity requires the introduction of certain degree of flexibility. However, flexibility cannot be introduced indiscriminately because it would lead to a loss of binding affinity and specificity. Recently, structure-based thermodynamic strategies aimed at developing adaptative ligands that target heterogeneous sites have been proposed. In this article, these strategies are discussed within the context of the development of second generation HIV-1 protease inhibitors.

Original languageEnglish (US)
Pages (from-to)82-88
Number of pages7
JournalJournal of Cellular Biochemistry
Volume84
Issue numberSUPPL. 37
DOIs
StatePublished - 2001

Fingerprint

Drug Design
Pharmaceutical Preparations
Binding Sites
HIV Protease Inhibitors
Thermodynamics
Molecules
Protease Inhibitors
Ligands
Mutation
Geometry

Keywords

  • AIDS
  • Drug design
  • Drug resistance
  • Genomic diversity
  • HIV

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Cite this

Incorporating target heterogeneity in drug design. / Velazquez-Campoy, Adrian; Freire, Ernesto I.

In: Journal of Cellular Biochemistry, Vol. 84, No. SUPPL. 37, 2001, p. 82-88.

Research output: Contribution to journalArticle

Velazquez-Campoy, Adrian ; Freire, Ernesto I. / Incorporating target heterogeneity in drug design. In: Journal of Cellular Biochemistry. 2001 ; Vol. 84, No. SUPPL. 37. pp. 82-88.
@article{0191c72012d84d73a3019ab3d2ee7de2,
title = "Incorporating target heterogeneity in drug design",
abstract = "Traditionally, structure-based drug design has been predicated on the idea of the lock-and-key hypothesis, i.e., the ideal drug should have a structure that complements the target site structurally and energetically. The implementation of this idea has lead to the development of drug molecules that are conformationally constrained and pre-shaped to the geometry of the selected target. The main drawback of this strategy is that conformationally constrained molecules cannot accommodate to variability in the target and, therefore, lose significant binding affinity even in the presence of small changes in the target site. There are three common situations that lead to binding site heterogeneity: (1) genetic diversity; (2) drug resistant mutations; and (3) binding site dynamics. The development of drugs that effectively deal with target heterogeneity requires the introduction of certain degree of flexibility. However, flexibility cannot be introduced indiscriminately because it would lead to a loss of binding affinity and specificity. Recently, structure-based thermodynamic strategies aimed at developing adaptative ligands that target heterogeneous sites have been proposed. In this article, these strategies are discussed within the context of the development of second generation HIV-1 protease inhibitors.",
keywords = "AIDS, Drug design, Drug resistance, Genomic diversity, HIV",
author = "Adrian Velazquez-Campoy and Freire, {Ernesto I}",
year = "2001",
doi = "10.1002/jcb.10068",
language = "English (US)",
volume = "84",
pages = "82--88",
journal = "Journal of Cellular Biochemistry",
issn = "0730-2312",
publisher = "Wiley-Liss Inc.",
number = "SUPPL. 37",

}

TY - JOUR

T1 - Incorporating target heterogeneity in drug design

AU - Velazquez-Campoy, Adrian

AU - Freire, Ernesto I

PY - 2001

Y1 - 2001

N2 - Traditionally, structure-based drug design has been predicated on the idea of the lock-and-key hypothesis, i.e., the ideal drug should have a structure that complements the target site structurally and energetically. The implementation of this idea has lead to the development of drug molecules that are conformationally constrained and pre-shaped to the geometry of the selected target. The main drawback of this strategy is that conformationally constrained molecules cannot accommodate to variability in the target and, therefore, lose significant binding affinity even in the presence of small changes in the target site. There are three common situations that lead to binding site heterogeneity: (1) genetic diversity; (2) drug resistant mutations; and (3) binding site dynamics. The development of drugs that effectively deal with target heterogeneity requires the introduction of certain degree of flexibility. However, flexibility cannot be introduced indiscriminately because it would lead to a loss of binding affinity and specificity. Recently, structure-based thermodynamic strategies aimed at developing adaptative ligands that target heterogeneous sites have been proposed. In this article, these strategies are discussed within the context of the development of second generation HIV-1 protease inhibitors.

AB - Traditionally, structure-based drug design has been predicated on the idea of the lock-and-key hypothesis, i.e., the ideal drug should have a structure that complements the target site structurally and energetically. The implementation of this idea has lead to the development of drug molecules that are conformationally constrained and pre-shaped to the geometry of the selected target. The main drawback of this strategy is that conformationally constrained molecules cannot accommodate to variability in the target and, therefore, lose significant binding affinity even in the presence of small changes in the target site. There are three common situations that lead to binding site heterogeneity: (1) genetic diversity; (2) drug resistant mutations; and (3) binding site dynamics. The development of drugs that effectively deal with target heterogeneity requires the introduction of certain degree of flexibility. However, flexibility cannot be introduced indiscriminately because it would lead to a loss of binding affinity and specificity. Recently, structure-based thermodynamic strategies aimed at developing adaptative ligands that target heterogeneous sites have been proposed. In this article, these strategies are discussed within the context of the development of second generation HIV-1 protease inhibitors.

KW - AIDS

KW - Drug design

KW - Drug resistance

KW - Genomic diversity

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=0036166136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036166136&partnerID=8YFLogxK

U2 - 10.1002/jcb.10068

DO - 10.1002/jcb.10068

M3 - Article

C2 - 11842432

AN - SCOPUS:0036166136

VL - 84

SP - 82

EP - 88

JO - Journal of Cellular Biochemistry

JF - Journal of Cellular Biochemistry

SN - 0730-2312

IS - SUPPL. 37

ER -